APGE

Apogee TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-22

View Chart

Peers tracked

U.S. public peers

Grade Position

Below peers

vs peer average

APGE vs peer average

31/100

APGE vs. peer average (D vs. C)

Grade spread

A 1 · B 3 · C 4 · D 1 · F 1

Graded peers loaded

Coverage

10 graded

100% of tracked

Peer overview

REGN is the first available peer comparator.

Regeneron is a direct benchmark because Apogee is positioning zumilokibart against Dupixent in AD, and Apogee's own APG279 study is running head-to-head versus DUPIXENT.

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerREGNRegeneron

APGE

Apogee Therapeutics

REGN

Regeneron

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Defensive

Constructive

Open Side-by-Side Comparison Compare all

Grade position vs REGN

APGE / REGN

Grade Position

Below peers

APGE vs. peer average (D vs. C)

31/100

Momentum

APGE

Value

REGN

Sentiment

REGN

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs APGE

REGN

80/100

-2

LLY

80/100

-2

CYTK

Cytokinetics Inc Common

20/100

KRYS

Krystal Biotech Inc Common

60/100

-1

CORT

Corcept Therapeutics Inc. Common

60/100

-1

REGN is the first peer returned for this comparison set.